NI201400152A - Formulaciones antibióticas inyectables y sus métodos de uso - Google Patents

Formulaciones antibióticas inyectables y sus métodos de uso

Info

Publication number
NI201400152A
NI201400152A NI201400152A NI201400152A NI201400152A NI 201400152 A NI201400152 A NI 201400152A NI 201400152 A NI201400152 A NI 201400152A NI 201400152 A NI201400152 A NI 201400152A NI 201400152 A NI201400152 A NI 201400152A
Authority
NI
Nicaragua
Prior art keywords
methods
antibiotic formulations
injectable antibiotic
injectable
formulations
Prior art date
Application number
NI201400152A
Other languages
English (en)
Inventor
Al Alawi Fadil
Bork Olaf
Jain Rohit
Nanjan Karthigeyan
George Tucker Ian
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49949085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201400152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NZ613138A external-priority patent/NZ613138B2/en
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of NI201400152A publication Critical patent/NI201400152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una composición que incluye penetamato (PNT) o un equivalente farmacéutico del mismo; y al menos un vehículo oleoso.
NI201400152A 2012-07-17 2014-12-19 Formulaciones antibióticas inyectables y sus métodos de uso NI201400152A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ60129912 2012-07-17
NZ61017513 2013-05-03
NZ613138A NZ613138B2 (en) 2013-07-12 Injectable antibiotic formulations and their methods of use

Publications (1)

Publication Number Publication Date
NI201400152A true NI201400152A (es) 2015-03-27

Family

ID=49949085

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400152A NI201400152A (es) 2012-07-17 2014-12-19 Formulaciones antibióticas inyectables y sus métodos de uso

Country Status (30)

Country Link
US (1) US10376585B2 (es)
EP (1) EP2874624B8 (es)
JP (1) JP6189437B2 (es)
KR (1) KR102113822B1 (es)
CN (1) CN104470517B (es)
AU (1) AU2013290826B2 (es)
BR (1) BR112014031083B1 (es)
CA (1) CA2875351C (es)
CL (1) CL2014003423A1 (es)
CO (1) CO7240359A2 (es)
CR (1) CR20140550A (es)
DK (1) DK2874624T3 (es)
DO (1) DOP2014000288A (es)
ES (1) ES2752034T3 (es)
HR (1) HRP20191730T1 (es)
HU (1) HUE046427T2 (es)
IL (1) IL236713B (es)
LT (1) LT2874624T (es)
MX (1) MX358248B (es)
MY (1) MY172561A (es)
NI (1) NI201400152A (es)
PH (1) PH12014502716A1 (es)
PL (1) PL2874624T3 (es)
PT (1) PT2874624T (es)
RU (1) RU2643327C2 (es)
SI (1) SI2874624T1 (es)
SV (1) SV2014004882A (es)
UA (1) UA118654C2 (es)
WO (1) WO2014014363A1 (es)
ZA (1) ZA201409322B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934524B1 (en) * 2012-12-20 2019-03-27 Alleva Animal Health Limited Penethamate veterinary injectable formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49768B1 (en) * 1979-05-21 1985-12-11 Leo Pharm Prod Ltd 6beta-halopenicillanic acid derivatives
IE51516B1 (en) * 1980-10-06 1987-01-07 Leo Pharm Prod Ltd 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate
IL64009A (en) 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
IE51846B1 (en) 1980-11-17 1987-04-15 Leo Pharm Prod Ltd Pharmaceutical preparation for veterinary use and an appliance containing it
EP0115001B1 (de) 1982-12-28 1988-06-15 Bayer Ag Stabile Aminoglykosid-Penicillin-Injektionsformulierungen
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US20040022815A1 (en) 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20050143347A1 (en) * 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE102004025324A1 (de) * 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8679540B2 (en) * 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
AU2008316225B2 (en) * 2007-10-26 2014-06-19 Avivagen Inc. Compositions and methods for enhancing immune response
SI2294012T1 (sl) * 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN101822637A (zh) * 2009-12-31 2010-09-08 天津瑞普生物技术股份有限公司 一种含有β-内酰胺类抗生素的混悬注射剂
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
KR20140047617A (ko) * 2011-06-23 2014-04-22 바이엘 뉴질랜드 리미티드 마크로사이클릭 락톤 및 레바미솔을 포함하는 항-기생충 조성물 및 기생충 감염의 치료 방법
PE20142373A1 (es) 2011-12-23 2015-02-11 Bayer New Zealand Ltd Formulaciones de antibioticos
PT2819699T (pt) * 2012-02-27 2019-08-21 Bayer New Zealand Ltd Composições de libertação controlada e os seus métodos de utilização

Also Published As

Publication number Publication date
AU2013290826A1 (en) 2015-01-15
LT2874624T (lt) 2019-12-10
SV2014004882A (es) 2016-11-11
JP2015522608A (ja) 2015-08-06
RU2643327C2 (ru) 2018-01-31
PL2874624T3 (pl) 2020-07-27
EP2874624A1 (en) 2015-05-27
UA118654C2 (uk) 2019-02-25
IL236713B (en) 2018-05-31
CR20140550A (es) 2015-02-05
AU2013290826B2 (en) 2018-10-18
PT2874624T (pt) 2019-11-04
CN104470517B (zh) 2018-12-18
MY172561A (en) 2019-12-03
EP2874624B1 (en) 2019-08-21
MX358248B (es) 2018-08-10
US20150174248A1 (en) 2015-06-25
DK2874624T3 (da) 2019-11-11
DOP2014000288A (es) 2015-02-15
MX2014015927A (es) 2015-03-03
CA2875351A1 (en) 2014-01-23
HRP20191730T1 (hr) 2019-12-13
KR102113822B1 (ko) 2020-05-22
PH12014502716B1 (en) 2015-02-02
EP2874624A4 (en) 2015-12-02
BR112014031083A2 (pt) 2017-06-27
BR112014031083B1 (pt) 2021-06-15
HUE046427T2 (hu) 2020-03-30
JP6189437B2 (ja) 2017-08-30
CA2875351C (en) 2021-08-31
CL2014003423A1 (es) 2015-04-17
PH12014502716A1 (en) 2015-02-02
EP2874624B8 (en) 2019-10-02
CN104470517A (zh) 2015-03-25
ZA201409322B (en) 2015-12-23
KR20150036092A (ko) 2015-04-07
SI2874624T1 (sl) 2020-02-28
IL236713A0 (en) 2015-02-26
RU2015105251A (ru) 2016-09-10
US10376585B2 (en) 2019-08-13
CO7240359A2 (es) 2015-04-17
ES2752034T3 (es) 2020-04-02
WO2014014363A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
DOP2017000298A (es) Reguladores de nrf2
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
DOP2016000145A (es) Reguladores de nrf2
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CR20160419A (es) Nuevos compuestos biciclicos
UY37410A (es) Antagonistas de trpv4
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
DOP2013000307A (es) Antagonistas de trpv4
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
GT201500247A (es) Imidazopiridazinas sustituidas
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.